<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844074</url>
  </required_header>
  <id_info>
    <org_study_id>ONS-5010-001</org_study_id>
    <nct_id>NCT03844074</nct_id>
  </id_info>
  <brief_title>A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)</brief_title>
  <official_title>A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Outlook Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Outlook Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will examine the safety and effectiveness of ONS-5010 in participants
      with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as
      compared with ranibizumab.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) score</measure>
    <time_frame>Baseline, 11 months</time_frame>
    <description>BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in the best corrected visual acuity over time</measure>
    <time_frame>Baseline, monthly to 11 months</time_frame>
    <description>BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who gain at least 10 letters in the best corrected visual acuity score</measure>
    <time_frame>Baseline, 11 months</time_frame>
    <description>BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who gain at least 5 letters in the best corrected visual acuity score</measure>
    <time_frame>Baseline, 11 months</time_frame>
    <description>BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who lose fewer than 15 letters in the best corrected visual acuity score</measure>
    <time_frame>Baseline, 11 months</time_frame>
    <description>BCVA to be assessed as letters read using the ETDRS charts. A negative change represents a decrease in visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with visual-acuity Snellen equivalent of 20/200 or worse</measure>
    <time_frame>Baseline, 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with ocular adverse events, non-ocular adverse events, grade 3 and above laboratory abnormalities, and vital sign abnormalities</measure>
    <time_frame>11 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Wet Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONS-5010</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>1.25 mg, intravitreal injection</description>
    <arm_group_label>bevacizumab</arm_group_label>
    <other_name>ONS-5010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>0.5mg, intravitreal injection</description>
    <arm_group_label>ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active primary or recurrent Subfoveal Choroidal Neovascularization lesions secondary
             to Age-related macular degeneration (AMD) in the study eye

          -  Best corrected visual acuity of 20/40 to 20/320

          -  Study eye must:

               -  Have active leakage on Fluorescein Angiogram involving the fovea

               -  Have edema involving the fovea

               -  Be free of foveal scarring

               -  Be free of foveal atrophy

        Exclusion Criteria:

          -  Previous use of anti-VEGF or bevacizumab within 6 weeks

          -  Previous subfoveal focal laser photocoagulation in the study eye

          -  Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month
             preceding randomization

          -  Any concurrent intraocular condition in the study eye that may require medical or
             surgical intervention or contribute to vision loss within 1 year

          -  Active intraocular inflammation (grade trace or above) in the study eye

          -  Current vitreous haemorrhage in the study eye

          -  Polypoidal choroidal vasculopathy (PCV) confirmed by indocyanine green angiography
             (ICGA)

          -  History of idiopathic or autoimmune-associated uveitis in either eye

          -  Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye

          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure â‰¥30 mmHg
             despite treatment with anti-glaucoma medication)

          -  Premenopausal women not using adequate contraception

          -  Current treatment for active systemic infection

          -  Known allergy to any component of the study drug or history of allergy to fluorescein
             or indocyanine green, not amenable to treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer M Kissner, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Outlook Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Hurstville</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Essendon</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Glen Waverley</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subfoveal Choroidal Neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will not be shared until all global regulatory filings are complete.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

